How Analysts Feel About Accuray (NASDAQ:ARAY) After Decrease in Sellers?

October 13, 2017 - By Darrin Black

 How Analysts Feel About Accuray (NASDAQ:ARAY) After Decrease in Sellers?

Investors sentiment decreased to 1.04 in 2017 Q2. Its down 0.14, from 1.18 in 2017Q1. It dived, as 23 investors sold Accuray Incorporated shares while 27 reduced holdings. 13 funds opened positions while 39 raised stakes. 62.66 million shares or 8.31% less from 68.34 million shares in 2017Q1 were reported.
10,466 are held by Amalgamated State Bank. Sei Company has invested 0% in Accuray Incorporated (NASDAQ:ARAY). Royal Commercial Bank Of Canada stated it has 957 shares or 0% of all its holdings. Neuberger Berman Group Inc Lc has invested 0.03% of its portfolio in Accuray Incorporated (NASDAQ:ARAY). Walleye Trading Ltd Limited Liability Company holds 7,200 shares. Swiss Bancorporation holds 0% or 130,300 shares. 11,327 were reported by Peak6 Invs L P. Glenmede Na has invested 0% of its portfolio in Accuray Incorporated (NASDAQ:ARAY). Menta Cap Limited Liability Company invested in 0.33% or 578,463 shares. Ahl Prtn Ltd Liability Partnership has 0% invested in Accuray Incorporated (NASDAQ:ARAY). Great West Life Assurance Can invested in 0% or 5,069 shares. Principal Grp Inc Inc Inc has 16,920 shares for 0% of their portfolio. Schwab Charles Invest Mgmt owns 413,032 shares or 0% of their US portfolio. Nationwide Fund has 0% invested in Accuray Incorporated (NASDAQ:ARAY). Menlo Advisors accumulated 10,000 shares.

The stock of Accuray (NASDAQ:ARAY) registered a decrease of 3.78% in short interest. ARAY’s total short interest was 5.91M shares in October as published by FINRA. Its down 3.78% from 6.15M shares, reported previously. With 488,100 shares average volume, it will take short sellers 12 days to cover their ARAY’s short positions. The short interest to Accuray’s float is 7.68%.

The stock decreased 1.19% or $0.05 during the last trading session, reaching $4.15. About 505,209 shares traded. Accuray Incorporated (NASDAQ:ARAY) has declined 21.41% since October 13, 2016 and is downtrending. It has underperformed by 38.11% the S&P500.

Accuray Incorporated is a radiation oncology company. The company has market cap of $347.58 million. The Firm develops, makes and markets medical devices used in radiation therapy for the treatment of cancer patients. It currently has negative earnings. The Company’s products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform.

Accuray Incorporated (NASDAQ:ARAY) Ratings Coverage

Among 7 analysts covering Accuray (NASDAQ:ARAY), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. Accuray had 19 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of Accuray Incorporated (NASDAQ:ARAY) earned “Sector Perform” rating by RBC Capital Markets on Tuesday, December 22. Cowen & Co maintained the stock with “Buy” rating in Tuesday, July 18 report. RBC Capital Markets maintained Accuray Incorporated (NASDAQ:ARAY) on Friday, January 29 with “Sector Perform” rating. The stock has “Buy” rating by Zacks on Tuesday, August 25. Jefferies maintained it with “Buy” rating and $700 target in Wednesday, August 9 report. The rating was maintained by RBC Capital Markets with “Hold” on Wednesday, August 23. The firm has “Buy” rating given on Thursday, June 29 by Jefferies. The rating was upgraded by Zacks on Wednesday, August 5 to “Sell”. The firm has “Neutral” rating given on Friday, August 21 by BTIG Research. The stock has “Outperform” rating by Cowen & Co on Tuesday, September 13.

More news for Accuray Incorporated (NASDAQ:ARAY) were recently published by: Seekingalpha.com, which released: “Harder And Harder To Find A Spark With Accuray” on August 24, 2017. Prnewswire.com‘s article titled: “Accuray Incorporated Reports Inducement Grant Under NASDAQ Listing Rules” and published on October 04, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.